{"classes":[{"categories":[{"measurements":[{"comment":"NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.","groupId":"OG000","lowerLimit":"21.0","upperLimit":"NA","value":"21.7"},{"comment":"NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.","groupId":"OG001","lowerLimit":"12.6","upperLimit":"NA","value":"22.6"},{"comment":"NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.","groupId":"OG002","lowerLimit":"15.0","upperLimit":"NA","value":"NA"},{"comment":"NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.","groupId":"OG003","lowerLimit":"8.4","upperLimit":"NA","value":"17.9"},{"comment":"NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.","groupId":"OG004","lowerLimit":"39.7","upperLimit":"NA","value":"NA"},{"comment":"NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.","groupId":"OG005","lowerLimit":"33.9","upperLimit":"NA","value":"NA"},{"comment":"NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.","groupId":"OG006","lowerLimit":"11.7","upperLimit":"NA","value":"53.4"},{"groupId":"OG007","lowerLimit":"7.9","upperLimit":"26.1","value":"12.4"},{"comment":"NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.","groupId":"OG008","lowerLimit":"9.3","upperLimit":"NA","value":"NA"},{"comment":"NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.","groupId":"OG009","lowerLimit":"19.4","upperLimit":"NA","value":"24.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"}],"units":"Participants"}],"description":"Time of overall survival for participants treated with KZR-261.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1.8 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG000","title":"Dose 1"},{"description":"Participants received 3.6 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG001","title":"Dose 2"},{"description":"Participants received 7.2 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG002","title":"Dose 3"},{"description":"Participants received 12 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG003","title":"Dose 4"},{"description":"Participants received 18 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG004","title":"Dose 5"},{"description":"Participants received 27 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG005","title":"Dose 6"},{"description":"Participants received 40 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG006","title":"Dose 7"},{"description":"Participants received 60 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG007","title":"Dose 8"},{"description":"Participants received 80 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG008","title":"Dose 9"},{"description":"Participants received 60 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG009","title":"Melanoma Expansion Cohort"}],"paramType":"MEDIAN","populationDescription":"The Response Evaluable Population is defined as all participants who received at least 1 dose of study treatment (KZR-261) and who have a baseline and at least 1 post-baseline anti-tumor response assessment.","reportingStatus":"POSTED","timeFrame":"20 months","title":"Overall Survival of Participants Treated With KZR-261","type":"SECONDARY","unitOfMeasure":"weeks"}